1. Healthcare

  2. •

    Drug Manufacturers - Specialty & Generic
Juniper Pharmaceuticals, Inc.

Juniper Pharmaceuticals, Inc.

JNP
Juniper Pharmaceuticals, Inc.US flagNASDAQ
11.50
USD
- -
- -
Juniper Pharmaceuticals, Inc.
JNP
(NASDAQ)

Recent

price

11.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
TTM
FRC
2.19
4.79
3.49
4.22
2.89
4.64
5.54
4.57
4.97
3.99
2.37
2.6
2.95
3.49
5.06
4.62
5.09
Revenue per Share
-3.96
-4.56
-4.94
-1.81
-2.12
-2.25
-2.16
-3.1
-2.38
1.9
0.91
0.6
0.31
-0.2
0.55
-0.15
-0.09
Basic EPS, GAAP
-2.68
-4.88
-3.99
-1.28
-6.49
-1.25
-0.84
-1.29
-1.06
-0.25
0.31
0.58
0.44
-0.24
0.71
-0.07
-0.13
Free Cash Flow per Basic Share
0.04
0.04
0.03
0.03
0.03
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-31.44
-33.39
-35.4
-36.53
-33.97
-34.51
-35.79
-36.38
-30.27
-23.85
-22.68
-21.45
-21.67
-22.3
-21.98
-22.07
-21.37
Book Value per Share
-2.22
1.1
-2.45
-2.9
-2.5
-4.2
-4.53
-4.62
-2.23
1.91
2.87
2.92
2.56
2.58
2.82
2.92
3.57
Tangible Book Value per Share
4
5
5
5
6
6
7
7
9
11
11
11
11
11
11
11
11
Basic Weighted Avg Shares
9
22
18
22
17
30
36
32
46
43
26
29
32
38
55
50
56
Sales/Revenue/Turnover
-168.39
-87.36
-123.02
-32.81
-64.16
-27.37
-19.97
-40.88
2.57
47.36
14.32
25.66
11.75
-6.69
9.67
-6.17
-3.96
Operating Margin (%)
1
1
- -
- -
- -
8
8
5
3
- -
1
1
2
2
2
2
2
Depreciation Expense
-17
-21
-25
-9
-13
-14
-14
-22
-22
21
10
7
3
-2
6
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.19
0.03
0.34
22.57
- -
1.51
- -
- -
Effective Tax Rate (%)
-178.9
-94.36
-140.7
-42.23
-72.51
-48.24
-38.74
-67.93
-47.79
47.67
38.4
22.94
10.44
-5.68
10.9
-4.12
-1.77
Profit Margin (%)
5
34
9
-3
23
14
12
14
2
28
32
26
20
19
20
20
25
Working Capital
10
26
19
9
37
39
43
48
13
- -
- -
4
3
3
2
3
3
LT Debt
-8
6
-13
-15
18
2
-6
-14
-21
21
31
47
41
39
40
42
48
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
301.82
14.9
18.69
6.2
- -
12.32
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-7.87
-3.93
-2.76
-1.44
- -
-2.52
- -
-0.07
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
1
1
1
LT Borrowings
3
3
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
52
110
95

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
36
38
41
Cash, Cash Equivalents & STI
21
21
21
Accounts Receivable, Net
5
9
11
Inventories
6
6
6
Total Current Liabilities
16
10
16
Payables & Accruals
10
9
15
ST Debt
1
1
1
Deferred Revenue
6
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-32%
7.67%
4.38%
Free Cash Flow
-84.48%
-117.26%
-109.35%
Net Income, GAAP
-95.03%
-151.65%
-134.62%
Sales/Revenue/Turnover
8.42%
15.36%
-8.42%
Total Cash Common Dividend
- -
- -
1,539.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
12
12
12
21
55
2017
11
14
13
12
50
2018
16
15
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
0.03
-0.16
0.02
0.89
0.55
2017
-0.13
-0.04
-0.13
0.11
-0.15
2018
0.07
-0.14
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Isracann Biosciences Inc. (IPOT.CN)
MediPharm Labs Corp. (LABS.TO)
InterCure Ltd. (INCR)
DongKook Pharmaceutical Co., Ltd. (086450.KQ)
Greenrose Acquisition Corp. (GNRSW)
Alkem Laboratories Limited (ALKEM.BO)
Business
Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) operates as a diversified healthcare company focused on women's health therapeutics; it develops novel intra-vaginal products addressing unmet medical needs, including Crinone 8% progesterone gel marketed by Allergan plc in the U.S. and Merck KGaA in over 90 countries worldwide for progesterone supplementation in assisted reproductive technology; its pipeline features proprietary candidates such as JNP-0101 oxybutynin intra-vaginal ring for overactive bladder, JNP-0201 combination estrogen-progesterone ring for hormone replacement therapy, JNP-0301 progesterone ring for preterm birth prevention, and COL-1077 lidocaine gel for gynecologic pain. The company also offers contract services through Juniper Pharma Services, encompassing pharmaceutical product development, clinical trial supply manufacturing, analytical services, bioavailability enhancement for poorly soluble compounds via nano-milling, spray drying and hot-melt extrusion, and consulting to pharmaceutical clients globally. Founded in 1986 as Columbia Laboratories Inc. and renamed Juniper Pharmaceuticals in April 2015, it maintains headquarters in Boston, Massachusetts, with key operations including a CDMO facility in Nottingham, UK. In 2018, Catalent Inc. completed its $130 million acquisition of Juniper at $11.50 per share, integrating its formulation development, early-phase manufacturing capabilities and Juniper Pharma Services into Catalent's global network to bolster oral drug delivery and clinical supply services.